The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a retrospective analysis using the VALIDATE database, which aimed to compare the efficacy of the two currently FDA-approved hypomethylating agents (HMA), azacitidine and decitabine, in treating patients with higher-risk myelodysplastic syndromes (HR-MDS). No significant difference in overall survival (OS) was found between the two agents. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
